Welcome to our dedicated page for Corbus Pharmaceuticals Holdings news (Ticker: CRBP), a resource for investors and traders seeking the latest updates and insights on Corbus Pharmaceuticals Holdings stock.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage drug development company dedicated to creating innovative therapies for rare, chronic, and serious inflammatory and fibrotic diseases. The company's leading product candidate, Resunab™, is a pioneering oral anti-inflammatory drug designed to resolve inflammation through an endogenous pathway. Resunab™ is set to begin three Phase 2 clinical trials in 2015 targeting cystic fibrosis, diffuse systemic sclerosis (scleroderma), and dermatomyositis, all conditions where inflammation significantly contributes to disease progression. Additionally, Resunab™ has the potential to address other rare inflammatory diseases.
Corbus Pharmaceuticals is also a precision oncology company with a diversified portfolio aimed at tackling serious illnesses using scientific approaches to well-known biological pathways. The company's development pipeline includes several key candidates:
- CRB-701: A next-generation antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells, releasing a cytotoxic payload.
- CRB-601: An anti-integrin monoclonal antibody blocking TGFβ activation expressed on cancer cells.
- CRB-913: A second-generation, peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Recent developments include the FDA clearance of CRB-601 for a Phase 1 study expected to enroll the first patient in the summer of 2024. Additionally, the company completed a public offering in February 2024, raising $94.5 million, and reported $127 million in cash, cash equivalents, and investments as of February 2, 2024, extending their cash runway through March 31, 2027.
Corbus aims to use the net proceeds from their recent underwritten offering to further their clinical development pipeline, ensuring robust progress across their range of innovative therapies. The company's partnerships and collaborations, such as with CSPC Pharmaceutical Group, highlight their commitment to advancing their pipeline and translating scientific discoveries into effective treatments for patients worldwide.
Headquartered in Norwood, Massachusetts, Corbus Pharmaceuticals is at the forefront of the biotechnology field, continuously striving to bring first-in-class treatments to market, thereby addressing unmet medical needs and improving patient outcomes. For more information, visit corbuspharma.com.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The presentation will be available on-demand starting September 12, 2022, at 7:00 AM ET for registered attendees, accessible for 30 days on the conference platform. Corbus focuses on immunology and is committed to innovative treatments targeting serious illnesses, with a pipeline that includes anti-integrin monoclonal antibodies and small molecules for the endocannabinoid system.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) provided an update, highlighting promising pre-clinical data for CRB-601, showing enhanced anti-tumor activity when combined with anti-PD-1 therapy. The IND submission for CRB-601 is on track for mid-2023. The company reported a net loss of $13.2 million for Q2 2022, improved from $17.1 million year-over-year, with operating expenses significantly reduced. Cash reserves stand at $74 million, expected to sustain operations through Q1 2024. Corbus also explores partnerships for advancing its pipeline and non-dilutive funding.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented new preclinical data for its anti-αvβ8 integrin monoclonal antibody, CRB-601, at the NYAS Frontiers in Cancer Immunotherapy Conference. The data highlight CRB-601's significant anti-tumor effects, both as a standalone treatment and in combination with anti-PD-1 therapy, across various tumor models including immune-excluded ones. Notably, CRB-601 enhances T-cell proliferation and re-sensitizes tumors to checkpoint inhibition. The company is advancing towards an IND submission in the first half of 2023.
Corbus Pharmaceuticals (CRBP) reported promising pre-clinical data for CRB-601, showing enhanced anti-tumor activity in combination with anti-PD1 therapy. The IND submission for CRB-601 is on track for the first half of 2023. The company holds $86.8 million in cash, sufficient to fund operations into Q1 2024. They also noted a reduced net loss of $9.4 million for Q1 2022, down from $16 million in Q1 2021, mainly due to lower clinical and manufacturing costs. Corbus aims to expand its immuno-oncology pipeline through strategic partnerships.
Corbus Pharmaceuticals (NASDAQ: CRBP) presented its first preclinical data for CRB-601 at the AACR Annual Meeting on April 8-13, 2022. CRB-601, a monoclonal antibody, targets αvb8 integrin to inhibit TGFb activation in tumors. The data revealed significant tumor growth inhibition in a colon cancer model, enhancing CD8-positive T cell infiltration. The company plans to submit an IND for CRB-601 in H1 2023, aiming to explore its anti-tumor potential in conjunction with existing immune therapies. The full poster and corporate presentation are available on their website.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D., will participate in a fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 8:00 AM ET. The event will include virtual one-on-one meetings for registered investors. A live webcast will be available on the company’s website, with a replay accessible two hours post-event for 90 days. Corbus focuses on innovative immunology solutions targeting the immune system and cancer.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported its fourth quarter and year-end 2021 financial results, revealing a significant drop in revenue, totaling $0 for Q4 compared to approximately $658,000 in Q4 2020. The total revenue for 2021 was $882,000, down from $3.9 million in 2020. Operating expenses decreased by $11.5 million in Q4 and $69.9 million for the year, reaching approximately $10 million and $56.9 million, respectively. The company reported a net loss of $10.3 million for Q4 and $45.6 million for 2021. As of year's end, Corbus had $98.3 million in cash, expected to fund operations into Q1 2024.
Corbus Pharmaceuticals (NASDAQ: CRBP) has appointed Rachael Brake, Ph.D., as its new Chief Scientific Officer. Dr. Brake joins from Takeda Pharmaceuticals, bringing extensive experience in oncology drug development. She will advance Corbus' pipeline, focusing on TGFβ-targeting therapeutics and the endocannabinoid system. CEO Yuval Cohen emphasized her leadership as essential for the company's growth. Dr. Brake aims to enhance the impact of immuno-oncology therapies, especially with new acquisitions like CRB-601.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) provided updates and financial results for Q3 2021. The company is progressing its anti-integrin mAb program targeting solid tumors, with first patient dosing expected in H1 2023. Lenabasum's Phase 2 study data is anticipated in Q4 2021. Revenue decreased to approximately $97,000 from $1.23 million in 2020, while operating expenses fell to $14 million from $35.2 million due to reduced clinical costs. Corbus reported a net loss of $2.2 million, down significantly from $34.9 million year-over-year. The company holds $108 million in cash, funding operations into Q1 2024.
Corbus Pharmaceuticals Holdings, a leader in immunology, will have its CEO, Yuval Cohen, participate in a fireside chat at the Jefferies London Healthcare Conference from November 16-19, 2021. This event will be both virtual and in-person, giving attendees the opportunity to engage directly.
An audio webcast of the chat will be available on-demand starting November 18, at 8:00 AM GMT for registered attendees. The presentation aims to advance discussions on Corbus's innovative treatments targeting inflammation and fibrosis.
FAQ
What is the current stock price of Corbus Pharmaceuticals Holdings (CRBP)?
What is the market cap of Corbus Pharmaceuticals Holdings (CRBP)?
What diseases does Corbus Pharmaceuticals target?
What is Resunab™?
What are the key products in Corbus’ development pipeline?
Where is Corbus Pharmaceuticals headquartered?
What recent financial developments has Corbus Pharmaceuticals announced?
Who are Corbus Pharmaceuticals’ partners?
When is Corbus Pharmaceuticals expected to begin the Phase 1 study of CRB-601?
What is the focus of CRB-701?
What is the purpose of the recent underwritten offering by Corbus Pharmaceuticals?
How can potential investors learn more about Corbus Pharmaceuticals' offerings?
